Loading
A phase 2 trial of PM8002, Bevacizumab and Temozolomide in glioma & glioblastoma, run by BioNTech SE, now recruiting.
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma is a phase 2 interventional study registered as NCT07297212 by BioNTech SE, with 75 participants planned, started 2026-01-15 and due to reach its primary completion in 2028-01. Interventions recorded: Pumitamig, Bevacizumab and Temozolomide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bristol Myers Squibb, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares PM8002, BioNTech, Bristol Myers Squibb and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/